Navigation Links
Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
Date:3/14/2008

EXTON, Pa., March 14 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today the completion of enrollment of approximately 120 patients in its Phase II/III Study IT-A-008 investigating the Isolagen Therapy(TM) for the treatment of moderate to severe acne scars. Treatments, which will be administered at seven clinical sites across the U.S., have now commenced.

"We believe the Isolagen Therapy could hold great promise for the treatment of acne scars and are pleased to have completed this important clinical milestone as planned," said Declan Daly, Chief Executive Officer of Isolagen. "Concerning our pivotal clinical program on wrinkle correction, we expect to review the six month efficacy data on our Phase III study of the Isolagen Therapy prior to September 1, 2008. We have focused our resources to meet the goals of advancing this program and our acne program and we are attempting to raise additional funding," continued Daly. "We have reduced our average monthly cash burn rate, are actively pursuing strategic partners for out-licensing, and are attempting to sell our Switzerland facility in an effort to generate additional funds. We have a resolute management team in place who are committed to achieving these goals."

About the Isolagen Process(TM) and Isolagen Therapy(TM)

The Isolagen Process(TM) is an innovative cellular processing system which creates a natural, living cell therapy. By multiplying a patient's own collagen-producing cells or fibroblasts into tens of millions of new cells, a personalized treatment is created which is then returned to the patient's skin. This treatment, known as the Isolagen Therapy(TM), is designed to improve skin damage caused by the normal effects of aging, sun damage,
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
2. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
3. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
4. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
7. Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
8. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
9. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
10. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  ConvaTec today announced that it will report its ... Berger , CEO, and Ed Borkowski , CFO, ... via telephone. To participate in the conference call within ... To participate in the conference call outside the U.S. and ... ID is 72195398. Participants should dial in 10 minutes prior ...
(Date:5/17/2013)... Rico , May 17, 2013  Serving a region ... Puerto Rico , Caribbean Imaging and Radiation Therapy (CIRT, ... radiation therapy capabilities with the acquisition of an Elekta Versa ... . Versa HD offers clinicians the versatility to deliver conventional ... body, while also enabling treatment of highly complex cancers that ...
(Date:5/17/2013)... Conn. , May 17, 2013  Boehringer ... in respiratory disease at the American Thoracic Society ... PA , May 17 – 22. ... product approved for the treatment of chronic obstructive ... powder)], as well as investigational compounds for asthma, ...
Breaking Medicine Technology:Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... NEW YORK, Dec. 5, 2010 Pfizer Inc. (NYSE: ... of Directors has elected Ian C. Read, 57, currently ... Chief Executive Officer and Director. Mr. Read succeeds Jeffrey ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead ...
... EAST HANOVER, N.J., Dec. 3, 2010 A newly ... a first-line treatment regimen including Zometa® (zoledronic acid) significantly ... newly diagnosed multiple myeloma patients compared with a regimen ... independent of the effect of Zometa on bone complications ...
Cached Medicine Technology:Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 2Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 3Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 4Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 5Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 6Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 7Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients 8
(Date:5/18/2013)... In “Cooking with Spirits for the Spirit: A ... Hall Svisdahl’s new cookbook, readers are transported into the world ... the pickiest eater drool. “I dedicate this book to the ... , Found within the 364 pages of “Cooking with Spirits ... from fast and simple to gourmet. Each recipe greets the ...
(Date:5/18/2013)... MAY 19, 2013 The American Society for Gastrointestinal ... of endoscopy during the ninth annual ASGE Crystal Awards ... the ASGE Foundation, this year,s event will begin at ... Orlando, Fla. , Held in conjunction with Digestive ... finest in leadership, research and scientific pursuit. The event ...
(Date:5/18/2013)... MD (May 19, 2013) The American Gastroenterological ... its 2013 research scholars. This year,s honorees are ... gastroenterology, hepatology or related areas, and with this ... , "These young researchers are the future of ... scholars who are paving the way for promising ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Online watch retailer ... Rolex watch owners at a fraction of its ... luxury timepieces in the world, buyers are urged to take ... to buying a Rolex watch from a brick-and-mortar store, buyers ... Rolex watches priced at unbelievable rates. Although some buyers ...
(Date:5/18/2013)... Reporter , , FRIDAY, May 17 (HealthDay News) -- As ... what is considered the "bible" of modern psychiatry this ... "This is unprecedented, the amount of commentary and debate ... American Psychiatric Association (APA). "It,s been an interesting phenomenon, ... to evaluate it and then make your own determination ...
Breaking Medicine News(10 mins):Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4
... today announced that it has completed its first ... results from patient diaries indicating that Cuprindo™ is ... healthy volunteers, reported 100% compliance with the dosing ... daily over a seven day period. In addition, ...
... wide-ranging influence on so many areas of life that ... neurosocieties. To bring this community together, the European ... Science Foundation (ESF), has initiated a series of activities ... and ethical implications of new developments in the neurosciences. ...
... The law firm of Lieff,Cabraser Heimann & Bernstein, ... behalf of purchasers of the securities of American Dental,Partners, ... 10, 2005,and December 13, 2007, inclusive (the "Class Period")., ... Class Period,you may move the Court for appointment as ...
... keep Hillenbrand name as part of new parent company for ... Batesville Casket Company, ... doing business ... (NYSE: HB ) announced today that it has begun mailing a,notice ...
... 15 drugstore.com, inc.,(Nasdaq: DSCM ), a ... products, today announced that Dawn Lepore, chief executive,officer ... Pont, chief financial,officer, will be presenting at the ... 2008 and the Morgan Stanley Technology,Conference on March ...
... MLSS), the recognized leader in,advanced injection technologies, today announced that it will ... WHEN: Friday, February 22, 2008 - Sunday, February 24, 2008, ... McCormick Place Lakeside Center ... Chicago, Illinois, WHO: ...
Cached Medicine News:Health News:European Neuroscience and Society Network tackles neurosocieties head-on 2Health News:Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners, Inc. 2Health News:Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuits Have Been Filed Against American Dental Partners, Inc. 3Health News:Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation 2Health News:Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation 3Health News:Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation 4Health News:Hillenbrand Announces Mailing of Proxy Regarding Changing of Company Name in Conjunction with Planned Separation 5Health News:drugstore.com, inc. to Present at the Upcoming Jefferies 4th Annual Internet Conference and the Morgan Stanley Technology Conference 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 143rd Midwinter Meeting 2Health News:Milestone Scientific to Exhibit at the Chicago Dental Society's 143rd Midwinter Meeting 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: